

1 **Supplemental Table S1.** Elite controller characteristics.

Participant ID	Age (years)	Duration of HIV infection (years)	Number of detectable plasma viremia episodes (highest viral load in copies/ml)	CD4 count at baseline (cells/μl)	Plasma viremia at baseline (copies/ml)
A	62	6	0/26 over 6 years	670	<20
B	58	23	0/38 over 12.5 years	650	<20
C	44	14	1/54 over 14 years (51)	980	<20
D	67	23	8/35 over 9.5 years (372)	560	88

2 Participant characteristics have been previously published¹⁰

3

Supplemental Table S2. Baseline levels of cellular and soluble markers of microbial translocation, coagulation and inflammation in blood.

	HIV-	HIV+ ART-	EC
HLA-DR+ CD38+ on CD8 T cells, %	2.6 (1.5-6.2) N=7	24.4 (17.9-45.8)* N=10	6.0 (1.6-9.6)# N=4
CD4/CD8 ratio	1.8 (0.6-3.2) N=11	0.4 (0.2-1.2)* N=12	1.0 (0.9-1.1)#,* N=4
LPS, EU/ml	1.2 (1.2-1.4) N=8	1.6 (1.4-2.0)* N=12	1.3 (0.9-1.6) N=4
sCD14, µg/ml	1.5 (1.2-1.7) N=8	2.1 (1.8-2.4)* N=12	1.5 (0.9-1.8)# N=4
D-dimer, ng/ml	98.8 (55.4-220.9), N=11	166.2 (55.4-889.4)* N=10	146.3 (115.1-225.8)* N=4
CRP, mg/ml	501.2 (369.4-6104) N=6	1621.0 (348.7-8483) N=6	821.3 (347.5-1245) N=4
IL-6, pg/ml	1.1 (0.6-2.4) N=8	1.9 (0.9-7.6) N=12	1.9 (1.6-5.9)* N=4
IL-17, pg/ml	1.5 (1.0-2.6) N=8	2.09 (0.82-10.76) N=12	1.3 (0.73-1.51)# N=4
MIP-1β, pg/ml	52.0 (19.6-224.2) N=8	34.2 (24.8-54.3)* N=12	49.7 (30.9-82.5) N=4
IP-10, pg/ml	129.1 (83.4-316.8) N=8	295.5 (154.7-229.2)* N=12	160.3 (50.2-215.1)# N=4
TNFα, pg/ml	0.9 (0.5-65.4) N=8	1.7 (0.9-5.6)* N=12	0.7 (0.4-1.6)# N=4
IL-10, pg/ml	0.7 (0.4-1.4) N=8	1.5 (0.8-3.4)* N=12	0.5 (0.4-0.8)# N=4

CD8 T cell immune activation data has been previously published¹⁰

Median values (range); sample size variation was dependent on sample availability.

*, P<0.05 EC and HIV+ compared to HIV-

#, P<0.05 EC compared to HIV+